• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤-基质比在乳腺癌女性中的预后疗效：队列研究的荟萃分析

Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies.

作者信息

Jiang Pengli, Chen Yulong, Liu Bin

机构信息

Department of Breast Surgery, The Second Hospital of Jilin University, Changchun, China.

出版信息

Front Oncol. 2021 Dec 16;11:731409. doi: 10.3389/fonc.2021.731409. eCollection 2021.

DOI:10.3389/fonc.2021.731409
PMID:34976792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8716503/
Abstract

BACKGROUND

Tumor-stroma ratio (TSR) has been suggested as an emerging prognostic predictor in women with breast cancer. However, previous studies evaluating the association between TSR and survival in women with breast cancer showed inconsistent results. We performed a meta-analysis to systematically evaluate the possible prognostic role of TSR in breast cancer.

METHODS

Relevant cohort studies were obtained search of PubMed, Embase, and Web of Science databases. A random-effects model, which incorporated the potential heterogeneity, was used to pool the results.

RESULTS

Twelve cohort studies with 6175 patients were included. Nine of the 12 studies used 50% as the cutoff to divide the patients into those with stroma-rich (low TSR) and stroma-poor (high TSR) tumors. Pooled results showed that compared women with stroma-poor tumor, those with stroma-rich tumor were associated with worse survival outcomes (disease-free survival [DFS]: hazard ratio [HR] = 1.56, 95% confidence interval [CI]: 1.32 to 1.85, P < 0.001; overall survival [OS]: HR = 1.67, 95% CI: 1.46 to 1.91, P < 0.001; and cancer-specific survival [CSS]: HR = 1.75, 95% CI: 1.40 to 2.20, P < 0.001). Analysis limited to women with triple-negative breast cancer (TNBC) showed consistent results (DFS: HR: 2.07, 95% CI: 1.59 to 2.71, P < 0.001; OS: HR: 2.04, 95% CI: 1.52 to 2.73, P < 0.001; and CSS: HR: 2.40, 95% CI: 1.52 to 3.78, P < 0.001).

CONCLUSIONS

Current evidence from retrospective studies supports that tumor TSR is a prognostic predictor or poor survival in women with breast cancer.

摘要

背景

肿瘤间质比（TSR）已被认为是乳腺癌女性患者一种新出现的预后预测指标。然而，既往评估TSR与乳腺癌女性患者生存之间关联的研究结果并不一致。我们进行了一项荟萃分析，以系统评价TSR在乳腺癌中可能的预后作用。

方法

通过检索PubMed、Embase和Web of Science数据库获取相关队列研究。采用纳入潜在异质性的随机效应模型汇总结果。

结果

纳入了12项队列研究，共6175例患者。12项研究中有9项以50%作为临界值，将患者分为间质丰富（低TSR）和间质贫乏（高TSR）肿瘤患者。汇总结果显示，与间质贫乏肿瘤患者相比，间质丰富肿瘤患者的生存结局更差（无病生存[DFS]：风险比[HR]=1.56，95%置信区间[CI]：1.32至1.85，P<0.001；总生存[OS]：HR=1.67，95%CI：1.46至1.91，P<0.001；癌症特异性生存[CSS]：HR=1.75，95%CI：1.40至2.20，P<0.001）。仅限于三阴性乳腺癌（TNBC）女性患者的分析显示结果一致（DFS：HR：2.07，95%CI：1.59至2.71，P<0.001；OS：HR：2.04，95%CI：1.52至2.73，P<0.001；CSS：HR：2.40，95%CI：1.52至3.78，P<0.001）。

结论

来自回顾性研究的当前证据支持肿瘤TSR是乳腺癌女性患者生存预后的预测指标或提示生存较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/b70c020bbc1d/fonc-11-731409-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/f184a031f1ff/fonc-11-731409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/142a97e0e4c6/fonc-11-731409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/06ff09225fb2/fonc-11-731409-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/b70c020bbc1d/fonc-11-731409-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/f184a031f1ff/fonc-11-731409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/142a97e0e4c6/fonc-11-731409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/06ff09225fb2/fonc-11-731409-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3992/8716503/b70c020bbc1d/fonc-11-731409-g004.jpg

相似文献

1
Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies.肿瘤-基质比在乳腺癌女性中的预后疗效：队列研究的荟萃分析
Front Oncol. 2021 Dec 16;11:731409. doi: 10.3389/fonc.2021.731409. eCollection 2021.
2
Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis.肿瘤-基质比对非小细胞肺癌患者生存的预测作用：一项荟萃分析。
Pathol Oncol Res. 2022 Jan 21;27:1610021. doi: 10.3389/pore.2021.1610021. eCollection 2021.
3
Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis.肿瘤-间质比在直肠癌中的预后价值：一项系统评价和Meta分析
Front Oncol. 2021 May 26;11:685570. doi: 10.3389/fonc.2021.685570. eCollection 2021.
4
Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.肿瘤基质比是乳腺癌 5 年无病生存的潜在预测指标。
BMC Cancer. 2022 Oct 21;22(1):1082. doi: 10.1186/s12885-022-10183-5.
5
Tumor-stroma ratio(TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis.肿瘤间质比（TSR）作为消化系统癌症预后的潜在新预测因子：一项荟萃分析。
Clin Chim Acta. 2017 Sep;472:64-68. doi: 10.1016/j.cca.2017.07.003. Epub 2017 Jul 17.
6
Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival.肺切除术后非小细胞肺癌（NSCLC）患者的肿瘤-基质比（TSR）是生存的一个预后因素。
J Thorac Dis. 2017 Oct;9(10):4017-4026. doi: 10.21037/jtd.2017.09.29.
7
The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer.肿瘤间质比在 III 级或三阴性乳腺癌患者中的预后价值最具鉴别性。
Int J Cancer. 2020 Apr 15;146(8):2296-2304. doi: 10.1002/ijc.32857. Epub 2020 Jan 22.
8
Prognostic value of tumor-stroma ratio in clear cell renal cell carcinoma after surgery.肿瘤-基质比在透明细胞肾细胞癌术后的预后价值
Transl Androl Urol. 2024 May 31;13(5):679-687. doi: 10.21037/tau-23-666. Epub 2024 May 24.
9
Significance of Tumor-Stroma Ratio (TSR) in Predicting Outcomes of Malignant Tumors.肿瘤间质比（TSR）在预测恶性肿瘤预后中的意义。
Medicina (Kaunas). 2023 Jul 6;59(7):1258. doi: 10.3390/medicina59071258.
10
The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer.肿瘤-基质比及新开发的对常规苏木精-伊红染色切片进行计算机辅助定量分析在高级别浆液性卵巢癌中的预后价值
Res Sq. 2023 Nov 14:rs.3.rs-3511087. doi: 10.21203/rs.3.rs-3511087/v1.

引用本文的文献

1
Tumor-stroma proportion is associated with increased M2 macrophage abundance and predicts the resistance to immune checkpoint blockade in breast cancer.肿瘤-基质比例与M2巨噬细胞丰度增加相关，并可预测乳腺癌对免疫检查点阻断的耐药性。
Transl Oncol. 2025 Apr;54:102343. doi: 10.1016/j.tranon.2025.102343. Epub 2025 Mar 10.
2
Tumor‑stroma ratio as a clinical prognostic factor in colorectal carcinoma: A meta‑analysis of 7,934 patients.肿瘤-基质比作为结直肠癌的临床预后因素：对7934例患者的荟萃分析
Oncol Lett. 2025 Feb 19;29(4):190. doi: 10.3892/ol.2025.14936. eCollection 2025 Apr.
3
Inverse correlation between the amounts of lymphocytic infiltrate and stroma in breast carcinoma.

本文引用的文献

1
New Frontiers for Fairer Breast Cancer Care in a Globalized World.全球化世界中更公平乳腺癌护理的新前沿
Eur J Breast Health. 2021 Mar 31;17(2):86-94. doi: 10.4274/ejbh.galenos.2021.2021-1-1. eCollection 2021 Apr.
2
PROGNOSTIC VALUE OF TUMOR STROMA RATIO IN TRIPLE NEGATIVE BREAST CANCER.肿瘤基质比在三阴性乳腺癌中的预后价值。
Wiad Lek. 2021;74(3 cz 2):565-571.
3
The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.肿瘤基质分数的预后影响：基于机器学习的 16 个人类实体瘤类型分析。
乳腺癌中淋巴细胞浸润量与间质量之间的负相关。
Heliyon. 2024 Nov 9;10(22):e40295. doi: 10.1016/j.heliyon.2024.e40295. eCollection 2024 Nov 30.
4
Prognostic Significance of Tumor-Stroma Ratio (TSR) in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.肿瘤间质比（TSR）在头颈部鳞状细胞癌中的预后意义：系统评价和荟萃分析。
Cells. 2024 Oct 26;13(21):1772. doi: 10.3390/cells13211772.
5
Utility of Indigenously Developed Square Grid Method for Evaluation of Tumor-Stroma Ratio and Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma: A Pilot Study.本土研发的方格法在评估浸润性乳腺癌肿瘤-基质比及基质肿瘤浸润淋巴细胞中的应用：一项初步研究
Iran J Pathol. 2023 Summer;18(3):335-346. doi: 10.30699/IJP.2023.1989528.3063. Epub 2023 Jul 16.
6
Reassessing Breast Cancer-Associated Fibroblasts (CAFs) Interactions with Other Stromal Components and Clinico-Pathologic Parameters by Using Immunohistochemistry and Digital Image Analysis (DIA).通过免疫组织化学和数字图像分析（DIA）重新评估乳腺癌相关成纤维细胞（CAFs）与其他基质成分及临床病理参数的相互作用。
Cancers (Basel). 2023 Jul 27;15(15):3823. doi: 10.3390/cancers15153823.
7
Tumour-stroma ratio (TSR) in breast cancer: comparison of scoring core biopsies versus resection specimens.乳腺癌肿瘤间质比（TSR）：核心穿刺活检与切除标本的评分比较。
Virchows Arch. 2024 Oct;485(4):703-716. doi: 10.1007/s00428-023-03555-0. Epub 2023 May 18.
8
HbA1c Variability and the Risk of Dementia in Patients with Diabetes: A Meta-Analysis.糖化血红蛋白变异性与糖尿病患者痴呆风险的关系：一项荟萃分析。
Int J Clin Pract. 2022 Jan 31;2022:7706330. doi: 10.1155/2022/7706330. eCollection 2022.
EBioMedicine. 2021 Mar;65:103269. doi: 10.1016/j.ebiom.2021.103269. Epub 2021 Mar 9.
4
Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer.使用数字图像分析评估肿瘤间质比可预测三阴性和管腔型乳腺癌的生存率。
Cancers (Basel). 2020 Dec 13;12(12):3749. doi: 10.3390/cancers12123749.
5
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies.原发性和转移性乳腺癌的肿瘤微环境：对新型治疗策略的启示。
Int J Mol Sci. 2020 Oct 30;21(21):8102. doi: 10.3390/ijms21218102.
6
The hispanic landscape of triple negative breast cancer.三阴性乳腺癌的西班牙裔景观。
Crit Rev Oncol Hematol. 2020 Nov;155:103094. doi: 10.1016/j.critrevonc.2020.103094. Epub 2020 Sep 22.
7
Chemotherapy resistance and stromal targets in breast cancer treatment: a review.乳腺癌治疗中的化疗耐药和基质靶点：综述。
Mol Biol Rep. 2020 Oct;47(10):8169-8177. doi: 10.1007/s11033-020-05853-1. Epub 2020 Oct 1.
8
The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines.肿瘤微环境在开发成功的治疗性和继发性预防性乳腺癌疫苗中的作用。
Vaccines (Basel). 2020 Sep 14;8(3):529. doi: 10.3390/vaccines8030529.
9
The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer.肿瘤间质比在 III 级或三阴性乳腺癌患者中的预后价值最具鉴别性。
Int J Cancer. 2020 Apr 15;146(8):2296-2304. doi: 10.1002/ijc.32857. Epub 2020 Jan 22.
10
The intra-tumoural stroma in patients with breast cancer increases with age.乳腺癌患者肿瘤内间质随年龄增长而增加。
Breast Cancer Res Treat. 2020 Jan;179(1):37-45. doi: 10.1007/s10549-019-05422-6. Epub 2019 Sep 18.